ABL Bio
Business Services · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
16 Daewangpangyo-ro Fl 2 712, Seongnam-s...Phone Number
+82 3180189800Website
www.ablbio.comRevenue
$14.4 MillionIndustry
About ABL Bio
ABL Bio Org Chart
Is ABL Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once ABL Bio has new funding data
Click to see if ABL Bio had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ABL Bio
Product Launch: Get notified when ABL Bio launches new products
Earning: See what the market has to say on ABL Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if ABL Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if ABL Bio is spiking on competitors!
ABL Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
ABL Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ABL Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ABL Bio.
ABL Bio Tech Stack
A closer look at the technologies used by ABL Bio
Most Recent Scoops
ABL Bio News & Media
Eyes on Asia: ABL Bio, Eli Lilly, Celltrion - BioXconomy
BioXconomy presents the Asia biopharma and healthcare dealmaking highlights for the week ending November 9, 2025.ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in...ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
- MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio's ABL103 in a Phase 1b/2 clinical trial SEONGNAM, South Korea, Oct. 4, 2024 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a...Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
BEIJING--(BUSINESS WIRE)-- #ADC--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs). Biocytogen’s RenLi
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ABL Bio
ABL Bio is a research-led biotechnology company, a pioneer in bispecific antibodies for immuno-oncology and neurodegenerative diseases. Delivering new approaches to address the highest unmet needs, the company is committed to improving the lives of people all over the world.... Read More
